Allogene Therapeutics, Inc. (ALLO) stock
ALLONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.74−0.06 (-7.79%)
Close on Nov 17, 2026Market cap $257.08MP/E –Yield 0.00%
Allogene Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Allogene Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$180.32M. For fiscal 2025 it was -$209.32M. The highest annual figure on record is -$180.19M in fiscal 2021.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$209.32M | – |
| FY2024 | Dec 31, 2024 | -$273.20M | – |
| FY2023 | Dec 31, 2023 | -$327.74M | – |
| FY2022 | Dec 31, 2022 | -$335.54M | – |
| FY2021 | Dec 31, 2021 | -$180.19M | – |
| FY2020 | Dec 31, 2020 | -$258.24M | – |
| FY2019 | Dec 31, 2019 | -$202.01M | – |
| FY2018 | Dec 31, 2018 | -$192.84M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$46.92M | – |
| Q1 FY2026 | Mar 31, 2026 | -$46.09M | – |
| Q4 FY2025 | Dec 31, 2025 | -$42.40M | – |
| Q3 FY2025 | Sep 30, 2025 | -$44.90M | – |
| Q2 FY2025 | Jun 30, 2025 | -$56.82M | – |
| Q1 FY2025 | Mar 31, 2025 | -$65.19M | – |
| Q4 FY2024 | Dec 31, 2024 | -$60.49M | – |
| Q3 FY2024 | Sep 30, 2024 | -$71.77M | – |
| Q2 FY2024 | Jun 30, 2024 | -$71.43M | – |
| Q1 FY2024 | Mar 31, 2024 | -$69.50M | – |
| Q4 FY2023 | Dec 31, 2023 | -$85.11M | – |
| Q3 FY2023 | Sep 30, 2023 | -$63.00M | – |
| Q2 FY2023 | Jun 30, 2023 | -$80.54M | – |
| Q1 FY2023 | Mar 31, 2023 | -$99.09M | – |
| Q4 FY2022 | Dec 31, 2022 | -$96.40M | -5747.0% |
| Q3 FY2022 | Sep 30, 2022 | -$82.51M | – |
| Q2 FY2022 | Jun 30, 2022 | -$76.62M | – |
| Q1 FY2022 | Mar 31, 2022 | -$80.01M | – |
| Q4 FY2021 | Dec 31, 2021 | $1.71M | – |
| Q3 FY2021 | Sep 30, 2021 | -$77.67M | – |
| Q2 FY2021 | Jun 30, 2021 | -$71.03M | – |
| Q1 FY2021 | Mar 31, 2021 | -$33.20M | – |
| Q4 FY2020 | Dec 31, 2020 | -$69.36M | – |
| Q3 FY2020 | Sep 30, 2020 | -$68.04M | – |
| Q2 FY2020 | Jun 30, 2020 | -$63.16M | – |
| Q1 FY2020 | Mar 31, 2020 | -$57.68M | – |
| Q4 FY2019 | Dec 31, 2019 | -$64.58M | – |
| Q3 FY2019 | Sep 30, 2019 | -$55.01M | – |
| Q2 FY2019 | Jun 30, 2019 | -$45.96M | – |
| Q1 FY2019 | Mar 31, 2019 | -$36.46M | – |
| Q4 FY2018 | Dec 31, 2018 | -$33.05M | – |
| Q3 FY2018 | Sep 30, 2018 | -$22.19M | – |
| Q2 FY2018 | Jun 30, 2018 | -$135.01M | – |
| Q1 FY2018 | Mar 31, 2018 | -$2.60M | – |
See a number that looks wrong?